Successful treatment of life-threatening Candida peritonitis in a child with abdominal non-hodgkin lymphoma using efungumab and amphotericin B colloid dispersion

Journal of Pediatric Hematology/Oncology

Volumn 32, Issue 2, 2010, Pages 128-130

  Krenova, Zdenka ^a   Pavelka, Zdenek ^a   Lokaj, Petr ^a   Skotakova, Jarmila ^b   Kocmanova, Ivana ^b   Teyschl, Otakar ^a   Kren, Leos ^b   Mudry, Peter ^a   Sterba, Jaroslav ^a  

^a Children's Hospital   (Czech Republic)

^b UNIVERSITY HOSPITAL BRNO   (Czech Republic)

Author keywords

Candida peritonitis; Child cancer; Eefungumab

Indexed keywords

AMPHOTERICIN B CHOLESTEROL SULFATE; CASPOFUNGIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; EFUNGUMAB; ETOPOSIDE; FLUCONAZOLE; IFOSFAMIDE; MEROPENEM; METHOTREXATE; METRONIDAZOLE; PREDNISONE; RECOMBINANT ANTIBODY; RITUXIMAB; UNCLASSIFIED DRUG; VANCOMYCIN; VINCRISTINE;

ABDOMEN; ABDOMINAL ABSCESS; ARTICLE; BLASTOCYST; CANDIDA ALBICANS; CANDIDIASIS; CASE REPORT; CHILD; DETERIORATION; DRUG TREATMENT FAILURE; EMERGENCY SURGERY; FEVER; HUMAN; HUMAN TISSUE; LARGE CELL LYMPHOMA; LOW DRUG DOSE; MALE; NONHODGKIN LYMPHOMA; PERITONITIS; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; SCHOOL CHILD; SMALL INTESTINE PERFORATION; TREATMENT OUTCOME;

ABDOMINAL NEOPLASMS; AMPHOTERICIN B; ANTIBODIES, MONOCLONAL; ANTIFUNGAL AGENTS; CANDIDIASIS; CHILD; DRUG THERAPY, COMBINATION; HSP90 HEAT-SHOCK PROTEINS; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; PERITONITIS;

EID: 77949446523     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/MPH.0b013e3181cb49a8     Document Type: Article

References (11)

1. Rosen GP, Nielsen K, Glenn S, et al. Invasive fungal infections in pediatric oncology patients: 11-years experience at a single institution. J Pediatr Hematol Oncol. 2005;27:135-140
2. Hovi L, Saxen H, Saarinen-Pikhala UM, et al. Prevention and monitoring of invasive fungal infections in pediatric patients with cancer and hematologic disorders. Pediatr Blood Cancer. 2007;48:28-34
3. Falagas ME, Apostolou KE, Pappas VD. Attributable mortality of candidemia: a systematic review of matched cohort and case-control studies. Eur J Clin Microbiol Infect Dis. 2006;25:419-425
4. Wingard JR, White MH, Anaissie E, et al. A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph/ABLC Collaborative Study Group. Clin Infect Dis. 2000;31:1155-1163
5. Jorgensen KJ, Gotzsche PC, Johansen HK. Voriconazole versus amphotericin B in patients with neutropenia. Cochrane Database Syst Rev. 2006;25:CD004707
6. Vogelsinger H, Weiler S, Djanani A, et al. Amphotericin B tissue distribution in autopsy material after treatment with liposomal amphotericin B and amphotericin B colloidal dispersion. J Antimicrob Chemother. 2006;57:1153-1160
7. Mayer J, Doubek M, Doubek J, et al. Reduced nephrotoxicity of conventional amphotericin B therapy after minimal nephroprotective measures: animal experiments and clinical study. J Infect Dis. 2002;186:378-388
8. Walsh TJ, Teppler H, Donowitz GR, et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistant fever and neutropenia. N Engl J Med. 2004;351:1391-1402
9. Matthews RC, Burnie JP. Human recombinant antibody to HSP90: a natural partner in combination therapy. Curr Mol Med. 2005;5:403-411
10. Pachl J, Svoboda P, Jacobs F, et al. A randomized, blinded, multicenter trial of lipid associated amphotericin B alone versus in combination with an antibody-based inhibitor of heat shock protein 90 in patients with invasive candidiasis. Clin Infect Dis. 2006;42:1404-1413
11. Woessmann W, Seidemann K, Mann G, et al. The impact of the methotrexate administration schedule and dose in the treatment of children and adolescents with B-cell neoplasms: a report of the BFM Group Study NHL-BFM95. Blood. 2005;105:948-958